期刊文献+

甲氨蝶呤联合环磷酰胺对胶原诱导性关节炎大鼠炎症的研究 被引量:1

原文传递
导出
摘要 甲氨蝶呤(MTX)与环磷酰胺(CTX)小剂量按周期间歇给药治疗类风湿关节炎(rheumatoid arthritis,RA),取得了显著疗效,明显降低了不良反应。肿瘤坏死因子(TNF)-α在RA的滑膜炎及软骨和骨的破坏中起着主导作用。本研究从MTX和CTX对胶原诱导性关节炎(CIA)大鼠炎症的治疗作用,并检测TNF—α的水平,探讨二者联合的协同效应及机制。
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2009年第8期581-582,I0001,共3页 Chinese Journal of Rheumatology
基金 山西省自然科学基金(2007011116) 山西省卫生厅科技攻关项目(200614) 山西医科大学第二医院博士启动基金(20070405) 山西医科大学第二医院青年科学基金(10060101)
  • 相关文献

参考文献6

  • 1李小峰 王晓霞 王来远 等.联合甲氨蝶呤和环磷酰胺治疗类风湿关节炎114例分析[J].中华风湿病学杂志,2005,9:185-186.
  • 2Trentham DE, Townes AS, Kang AH. Autoimmunity to type Ⅱ collagen an experimental model of arthritis. J Exp Med, 1977, 146: 857-868.
  • 3Schett G, Middleton S, Bolon B, et al . Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models .Arthritis Rheum, 2005,52: 1604-1611.
  • 4Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional diseasemodifying antirheumatie drugs is sustained over time: the elevenyear results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum ,2009,60:1222-1231.
  • 5Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford), 2008, 47: 59-64.
  • 6Sethi G, Ahn KS, Sandur SK, et al. Indirubin enhances TNF- induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J Biol Chem, 2006, 281: 23425-23435.

共引文献9

同被引文献16

  • 1成虎.难治性类风湿关节炎38例治疗观察[J].中国社区医师(医学专业),2007,9(9):85-85. 被引量:2
  • 2Numohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and bio- logic agents in rheumatoid arthritis. Drugs, 2005, 65: 661-694.
  • 3Van der Heijden JW, Dijkmans BA, Scheper RJ, et al. Drug insight: resistance to methotrexate and other disease-modifying antirheumatic drugs-from bench to bedside. Nat Clin Pract Rheumatol, 2007, 3: 26-34.
  • 4Mittal N, Mittal R, Sharma A, et al. Treatment failure withdisease-modifying antirheumatic drugs in rheumatoid arthritis patients. Singapore Med J, 2012, 53: 532-536.
  • 5Loo TW, Bartlett MC, Clarke DM, et al. Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of hu- man P-glycoprotein are close together on the cytoplasmic side of the membrane. J Biol Chem, 2004, 279: 7692-7697.
  • 6Lindqvist E, Saxne T, Geborek P, et al. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis, 2002, 61 : 1055- 1059.
  • 7Morgan C, Lunt M, Brightwell H, et al. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis, 2003, 62: 15-19.
  • 8Agarwal V, Mittal SK, Misra R. Expression of muhidrug re- sistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis. Clin Rheumatol, 2009, 28: 427-433.
  • 9Tsujimura S, Saito K, Nawata M, et al. Overcoming drug re- sistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis, 2008, 67: 380-388.
  • 10Tsujimura S, Saito K, Nakayamada S, et al. Etanercept over- comes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. Mod Rheumatol, 2010, 202: 139-146.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部